FDAnews
www.fdanews.com/articles/114095-orexo-signs-agreement-for-abstral-in-china

Orexo Signs Agreement for Abstral in China

January 27, 2009
Orexo and the Chinese pharmaceutical company NovaMed Pharmaceuticals have signed an exclusive licensing and distribution agreement that grants NovaMed rights to seek approval for Abstral, Orexo’s product for treatment of breakthrough cancer pain, in the People’s Republic of China, and if granted, to market and sell the product in that market.
Yahoo! Finance